Abstract:The ultrashort duration of laser-driven multi-MeV ion bursts offers the possibility of radiobiological studies at extremely high dose rates. Employing the TARANIS Terawatt laser at Queen’s University, the effect of proton irradiation at MeV-range energies on live cells has been investigated at dose rates exceeding 109 Gy/s as a single exposure. A clonogenic assay showed consistent lethal effects on V-79 live cells, which, even at these dose rates, appear to be in line with previously published results employin… Show more
“…Both radiobiological results are in good agreement with a complementary experiment performed at the Munich Tandem Van-de-Graaf accelerator [37,38] and a recent study of the RBE of intense single pulses of LDPR, where the dose applied to the cells was varying across the probe and analyzed retrospectively for individual irradiated areas [26]. Making use of different pulse modes of the Tandem accelerator, the first study focused on the dependence of the RBE on the peak dose rate by comparing the effect of short-pulses (few nanoseconds) and continuous beams of 20 MeV protons, while the latter directly made use of the intrinsically high peak dose rates of LDPR of up to few Gy per pulse.…”
Section: Discussionsupporting
confidence: 71%
“…This work is building on previous work from our group [22] and the radiobiological results are consistent with first experiments performed by Yogo et al [24,25] and a recent single-pulse study of the RBE by Doria et al [26] with retrospective dose evaluation.…”
Proton beams are a promising tool for the improvement of radiotherapy of cancer, and compact laserdriven proton radiation (LDPR) is discussed as an alternative to established large-scale technology facilitating wider clinical use. Yet, clinical use of LDPR requires substantial development in reliable beam generation and transport, but also in dosimetric protocols as well as validation in radiobiological studies. Here, we present the first dose-controlled direct comparison of the radiobiological effectiveness of intense proton pulses from a laser-driven accelerator with conventionally generated continuous proton beams, demonstrating a first milestone in translational research. Controlled dose delivery, precisely online and offline monitored for each out of *4,000 pulses, resulted in an unprecedented relative dose uncertainty of below 10 %, using approaches scalable to the next translational step toward radiotherapy application.
“…Both radiobiological results are in good agreement with a complementary experiment performed at the Munich Tandem Van-de-Graaf accelerator [37,38] and a recent study of the RBE of intense single pulses of LDPR, where the dose applied to the cells was varying across the probe and analyzed retrospectively for individual irradiated areas [26]. Making use of different pulse modes of the Tandem accelerator, the first study focused on the dependence of the RBE on the peak dose rate by comparing the effect of short-pulses (few nanoseconds) and continuous beams of 20 MeV protons, while the latter directly made use of the intrinsically high peak dose rates of LDPR of up to few Gy per pulse.…”
Section: Discussionsupporting
confidence: 71%
“…This work is building on previous work from our group [22] and the radiobiological results are consistent with first experiments performed by Yogo et al [24,25] and a recent single-pulse study of the RBE by Doria et al [26] with retrospective dose evaluation.…”
Proton beams are a promising tool for the improvement of radiotherapy of cancer, and compact laserdriven proton radiation (LDPR) is discussed as an alternative to established large-scale technology facilitating wider clinical use. Yet, clinical use of LDPR requires substantial development in reliable beam generation and transport, but also in dosimetric protocols as well as validation in radiobiological studies. Here, we present the first dose-controlled direct comparison of the radiobiological effectiveness of intense proton pulses from a laser-driven accelerator with conventionally generated continuous proton beams, demonstrating a first milestone in translational research. Controlled dose delivery, precisely online and offline monitored for each out of *4,000 pulses, resulted in an unprecedented relative dose uncertainty of below 10 %, using approaches scalable to the next translational step toward radiotherapy application.
“…Therefore, L-IBT poses a whole new set of challenges on both physical and biological levels. Laser-driven irradiation technology with all the necessary main components (such as high power laser system and laser target to produce the particle beam, and also beam transport and monitoring as well as dose delivery technique) has already been developed to perform in-vitro cell [26][27][28][29][30][31][32] and small animal [24,26] irradiation with low energy LAP within radiobiological experiments. These recent promising results encourage a go-ahead with further L-IBT solutions.…”
Section: Laser Particle Acceleratormentioning
confidence: 99%
“…Therefore, new methods and techniques for beam transport, irradiation field formation and treatment planning [19][20][21], along with beam-monitoring, dosimetry and dose-controlled irradiation [22][23][24][25][26] are required. Moreover, determination of radio-biological effects induced by ultrashort intense particle bunches [26][27][28][29][30][31][32] is necessary. In addition to laser particle accelerator development, a parallel oncologyfocused research and development is essential to bring this highly promising technology to the clinics.…”
The recent advancements in the field of laserdriven particle acceleration have made Laser-driven Ion Beam Therapy (L-IBT) an attractive alternative to the conventional particle therapy facilities. To bring this emerging technology to clinical application, we introduce the broad energy assorted depth dose deposition model which makes efficient use of the large energy spread and high dose-per-pulse of Laser Accelerated Protons (LAP) and is capable of delivering homogeneous doses to tumors. Furthermore, as a key component of L-IBT solution, we present a compact iso-centric gantry design with 360°r otation capability and an integrated shot-to-shot energy selection system for efficient transport of LAP with large energy spread to the patient. We show that gantry size could be reduced by a factor of 2-3 compared to conventional gantry systems by utilizing pulsed air-core magnets.
“…These issues are addressed by Portz et al 10 ("A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy"), Cerofolini 11 ("Host-guest interaction in cancer and a reason for the poor efficiency of the immune system in its detection and termination") and Wiley and Haraldsen 12 ("The theory of modulated hormone therapy for the treatment of breast cancer in pre-and post-menopausal women"). The development of new technologies, such as laser driven ultra-fast high energy proton therapy by Doria et al 13 ("Biological effectiveness on live cells of laser driven protons at dose rates exceeding 10 9 Gy/s"), Alfano 14 explores using ultra-fast lasers to diagnose metastatic cancer cells ("Advances in ultrafast time resolved fluorescence physics for cancer detection in optical biopsy") while Solano et al 15 explore photo-acoustic imaging ("An experimental and theoretical approach to the study of the photoacoustic signal produced by cancer cells"). I was intrigued by the paper of Frieboes et al 16 which is a combination of sophisticated modeling of drug delivery to tumors coupled with new imaging technologies which will allow us to optimize modeling of drug delivery based upon observations.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.